Clinical application of antifungal pharmacodynamics

Current Fungal Infection Reports

Volumn 3, Issue 2, 2009, Pages 69-76

  Gallagher, Jason C ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ASPERGILLOSIS; BRAIN DISEASE; CANDIDA GLABRATA; CANDIDA KRUSEI; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FUNGICIDAL ACTIVITY; HUMAN; HYPOKALEMIA; INJECTION SITE REACTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; KIDNEY DYSFUNCTION; LIVER FUNCTION TEST; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; OROPHARYNX CANDIDIASIS; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SYSTEMIC MYCOSIS; VISUAL DISORDER;

EID: 77749296988     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-009-0010-1     Document Type: Review

References (45)

1. W.A. Craig 1998 Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1 10 9455502 10.1086/516284 1:CAS:528:DyaK1cXltVaqtw%3D%3D
2. W. Craig 1993 Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens Eur J Clin Microbiol Infect Dis 12 Suppl1 S6 S8 8477766 10.1007/BF02389870 1:CAS:528:DyaK3sXlvFCrtbk%3D
3. T.P. Lodise Jr B. Lomaestro G.L. Drusano 2007 Piperacillintazobactam for pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy Clin Infect Dis 44 357 363 17205441 10.1086/510590 1:CAS:528:DC%2BD2sXhvFSqt7c%3D
4. D.P. Nicolau C.D. Freeman P.P. Belliveau, et al. 1995 Experience with a once-daily aminoglycoside program administered to 2,184 adult patients Antimicrob Agents Chemother 39 650 655 7793867 1:CAS:528:DyaK2MXktFWltL0%3D
5. D. Andes 2006 Pharmacokinetics and pharmacodynamics of antifungals Infect Dis Clin North Am 20 679 697 16984875 10.1016/j.idc.2006.06.007
6. D. Andes 2004 Clinical utility of antifungal pharmacokinetics and pharmacodynamics Curr Opin Infect Dis 17 533 540 15640707 10.1097/00001432- 200412000-00005 1:CAS:528:DC%2BD2MXktlahsw%3D%3D
7. D. Andes D.J. Diekema M.A. Pfaller, et al. 2008 In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model Antimicrob Agents Chemother 52 539 550 18070979 10.1128/AAC.01061-07 1:CAS:528:DC%2BD1cXhtlSqu78%3D
8. E.S. Dodds R.H. Drew J.R. Perfect 2000 Antifungal pharmacodynamics: review of the literature and clinical applications Pharmacotherapy 20 1335 1355 11079283 10.1592/phco.20.17.1335.34901 1:CAS:528:DC%2BD3cXosVejsLo%3D
9. T. Gumbo 2007 Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies Curr Opin Infect Dis 20 587 591 17975408 10.1097/QCO.0b013e3282f1bea3 1:CAS:528:DC%2BD2sXht1CnsLrE
10. U. Theuretzbacher 2004 Pharmacokinetics/pharmacodynamics of echinocandins Eur J Clin Microbiol Infect Dis 23 805 812 15490294 10.1007/s10096-004-1228-z 1:CAS:528:DC%2BD2cXhtVSitLvF
11. D. Andes M. van Ogtrop 2000 In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model Antimicrob Agents Chemother 44 938 942 10722494 10.1128/AAC.44.4.938-942. 2000 1:CAS:528:DC%2BD3cXitFOlurs%3D
12. P. Francis T.J. Walsh 1992 Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy Clin Infect Dis 15 1003 1018 1457631 1:CAS:528: DyaK3sXhtl2jsL0%3D
13. A. Louie G.L. Drusano P. Banerjee, et al. 1998 Pharmacodynamics of fluconazole in a murine model of systemic candidiasis Antimicrob Agents Chemother 42 1105 1109 9593135 1:CAS:528:DyaK1cXislWltb8%3D
14. A.M. Stamm R.B. Diasio W.E. Dismukes, et al. 1987 Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis Am J Med 83 236 242 3303926 10.1016/0002-9343(87)90691-7 1:STN:280: DyaL2s3ps1Slug%3D%3D
15. R. Martino M. Subira M. Rovira alloPBSCT Infectious/Non-infectious Complications Subcommittees of the Grupo Espanol de Trasplante Hematopoyetico, et al. 2002 Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: Incidence and risk factors in 395 patients Br J Haematol 116 475 482 11841455 10.1046/j.1365-2141.2002.03259.x
16. J.C. Gallagher C. MacDougall E.S. Ashley J.R. Perfect 2004 Recent advances in antifungal pharmacotherapy for invasive fungal infections Expert Rev Anti Infect Ther 2 253 268 15482191 10.1586/14787210.2.2.253 1:CAS:528:DC%2BD2cXislyru7Y%3D
17. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2008.
18. P. Liu M. Muller H. Derendorf 2002 Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations Int J Antimicrob Agents 19 285 290 11978499 10.1016/S0924-8579(02)00024-9 1:CAS:528: DC%2BD38XjtVeisL8%3D
19. H.A. Gallis R.H. Drew W.W. Pickard 1990 Amphotericin B: 30 years of clinical experience Rev Infect Dis 12 308 329 2184499 1:STN:280: DyaK3c3jt1aqtg%3D%3D
20. D. Andes T. Stamsted R. Conklin 2001 Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model Antimicrob Agents Chemother 45 922 926 11181381 10.1128/AAC.45.3.922-926.2001 1:CAS:528: DC%2BD3MXhsFWgu7o%3D
21. N.P. Wiederhold V.H. Tam J. Chi, et al. 2006 Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis Antimicrob Agents Chemother 50 469 473 16436698 10.1128/AAC.50.2.469-473.2006 1:CAS:528: DC%2BD28XhsFegt78%3D
22. J. Adler-Moore R.T. Proffitt 2002 AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience J Antimicrob Chemother 49 Suppl1 21 30 11801577 1:CAS:528:DC%2BD38XhsFChtb8%3D
23. U. Eriksson B. Seifert A. Schaffner 2001 Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial BMJ 322 579 582 11238151 10.1136/bmj.322.7286.579 1:CAS:528: DC%2BD3MXis1Cjsrg%3D
24. A. Imhof R.B. Walter A. Schaffner 2003 Continuous infusion of escalated doses of amphotericin B deoxycholate: an openlabel observational study Clin Infect Dis 36 943 951 12684904 10.1086/368312 1:CAS:528:DC%2BD3sXjsl2qt7k%3D
25. A.Y. Peleg M.L. Woods 2004 Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients J Antimicrob Chemother 54 803 808 15308606 10.1093/jac/dkh403 1:CAS:528:DC%2BD2cXotVyqsLg%3D
26. P. Altmannsberger E. Holler R. Andreesen S.W. Krause 2007 Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule J Antimicrob Chemother 60 180 182 17537868 10.1093/jac/dkm147 1:CAS:528: DC%2BD2sXot1ert7c%3D
27. O.A. Cornely J. Maertens M. Bresnik, et al. 2007 Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) Clin Infect Dis 44 1289 1297 17443465 10.1086/514341 1:CAS:528:DC%2BD2sXmtFegtro%3D
28. T.J. Walsh E.J. Anaissie D.W. Denning, et al. 2008 Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 327 360 18177225 10.1086/525258 1:CAS:528:DC%2BD1cXitlKqt7c%3D
29. D.W. Denning P. Ribaud N. Milpied, et al. 2002 Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 563 571 11807679 10.1086/324620 1:CAS:528:DC%2BD38XitlCitbg%3D
30. D. Andes K. Marchillo T. Stamstad R. Conklin 2003 In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model Antimicrob Agents Chemother 47 3165 3169 14506026 10.1128/AAC.47.10.3165-3169.2003 1:CAS:528:DC%2BD3sXnvVWmtr8%3D
31. J. Smith N. Safdar V. Knasinski, et al. 2006 Voriconazole therapeutic drug monitoring Antimicrob Agents Chemother 50 1570 1572 16569888 10.1128/AAC.50.4.1570-1572.2006 1:CAS:528:DC%2BD28XjvFOrtrg%3D
32. A. Pascual T. Calandra S. Bolay, et al. 2008 Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes Clin Infect Dis 46 201 211 18171251 10.1086/524669 1:CAS:528: DC%2BD1cXhvVClsbY%3D
33. K. Tan N. Brayshaw K. Tomaszewski, et al. 2006 Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities J Clin Pharmacol 46 235 243 16432276 10.1177/0091270005283837 1:CAS:528:DC%2BD28XhsFejsb4%3D
34. A. Imhof D.J. Schaer U. Schanz U. Schwarz 2006 Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring Swiss Med Wkly 136 739 742 17183438 1:CAS:528:DC%2BD2sXhtVOisb0%3D
35. S. Trifilio R. Ortiz G. Pennick, et al. 2005 Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients Bone Marrow Transplant 35 509 513 15654347 10.1038/sj.bmt.1704828 1:CAS:528:DC%2BD2MXhsFWlsLs%3D
36. S. Trifilio G. Pennick J. Pi, et al. 2007 Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients Cancer 109 1532 1535 17351937 10.1002/cncr.22568 1:CAS:528:DC%2BD2sXlt1GmtL0%3D
37. D. Andes M. van Ogtrop 1999 Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model Antimicrob Agents Chemother 43 2116 2120 10471550 1:CAS:528:DyaK1MXlvVGrt7Y%3D
38. J.H. Rex M.A. Pfaller J.N. Galgiani, et al. 1997 Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards [see comment] Clin Infect Dis 24 235 247 9114154 1:CAS:528:DyaK2sXhsVeqtLo%3D
39. C.J. Clancy V.L. Yu A.J. Morris, et al. 2005 Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia Antimicrob Agents Chemother 49 3171 3177 16048920 10.1128/AAC.49.8.3171-3177.2005 1:CAS:528:DC%2BD2MXntFCht7g%3D
40. M.P. Pai R.S. Turpin K.W. Garey 2007 Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia Antimicrob Agents Chemother 51 35 39 17101684 10.1128/AAC.00474-06 1:CAS:528:DC%2BD2sXktVamtA%3D%3D
41. K.W. Garey M. Rege M.P. Pai, et al. 2006 Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin Infect Dis 43 25 31 16758414 10.1086/504810 1:CAS:528:DC%2BD28XntV2ks7w%3D
42. J.L. Rodriguez-Tudela B. Almirante D. Rodriguez-Pardo, et al. 2007 Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia Antimicrob Agents Chemother 51 3599 3604 17646421 10.1128/AAC.00296-07 1:CAS:528: DC%2BD2sXhtFGhtbjP
43. J.W. Baddley M. Patel S.M. Bhavnani, et al. 2008 Association of fluconazole pharmacodynamics with mortality in patients with candidemia Antimicrob Agents Chemother 52 3022 3028 18591269 10.1128/AAC.00116-08 1:CAS:528:DC%2BD1cXhtF2gtrjJ
44. T. Gumbo G.L. Drusano W. Liu, et al. 2007 Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia Antimicrob Agents Chemother 51 968 974 17194830 10.1128/AAC.01337-06 1:CAS:528:DC%2BD2sXis12js7s%3D
45. P.G. Pappas C.M. Rotstein R.F. Betts, et al. 2007 Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 883 893 17806055 10.1086/520980 1:CAS:528:DC%2BD2sXhtFOntr7I